Table 2 Univariate association between individual parameters and survival

From: Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Clinical and demographic markers

Genetic markers

Protein markers

     

P -value per subcellular localisation

Parameters

P -value

Parameters

P -value

Parameters

Membranous

Cytoplasmic

Granular

Nuclear

Age

0.49

       

R0 vs R1/R2

0.057

EGFR FISH

 

EGFR

0.63

0.10 (0.099a)

0

Adenocarcinoma vs all other

0.54

 No gain vs other

0.15

HER2

1

0.33

BAC vs all other

0.43

 High polysomy vs other

0.13

pAKT.473

0.22

0.62

Squamous cell vs all other

0.42

 Amplification vs other

0.72

pAKT.309

0.53

1

0.95

Large cell carcinoma vs all other

0.9

  

PTEN

0.63

0.69

Smoking (non vs current vs Former)

0.79

EGFR mutation

 

pERK

0.36

0.011

0.39

Stage (I vs II vs III)

0.04

 WT vs other

0.15

pSTAT3

0.97

0.50

0.056 (0.11b)

Stage (I vs II/III)

0.015 (0.03c)

 SNP vs other

0.70

pSTAT5

0.76

0.31

0.33

Pre-operative CT vs not

0.45

 Mutant vs other

0.33

E-cadherin

0.32

0.031

Post-operative CT vs not

0.5

  

Vimentin

0.29

0.80

0.45

Post-operative RT vs not

0.15

KRAS mutation

 

HIF-1α

0.55

Pre-operative chemo-radiation vs not

0.031d

 WT vs other

0.08

pCMET.1003

0.8

0.11

Other diseases vs not

0.37

 SNP vs other

0.84

pCMET.1349

0.49

0.69

  

 Mutant vs other

0.08

pCMET.1230

0.88

0.90

0.68

    

pCMET.1365

0.55

0.87

0.86

  1. Abbreviations: CT=chemotherapy; EGFR=epidermal growth factor receptor; FISH=fluorescent in situ hybridization; R0, R1, R2=resection1, 2, 3; RT=radiotherapy; SNP=single nucleotide polymorphism; WT=wild type.
  2. aEGFR C: P=0.10 for 0–100 vs 160–300; P=0.20 after adjustment for new division in data.
  3. b pSTAT3 N: P=0.056 for 0–200 vs 210+; P=0.11 after adjusting P-value.
  4. cP=0.03 after adjustment for tests leading to re-grouping.
  5. dOnly three patients received pre-operative chemo-radiation; thus this parameter will not be considered in any other analyses.